News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Novartis' LEE011 on fast track to challenge Ibrance US regulator grants fast review for breast cancer drug.
News GSK settles US bribery probe for $20m Actions of Chinese subsidiaries violated US bribery laws, says SEC.
Views & Analysis Astellas wins first Real-World Evidence prize at UK awards UK awards first to introduce a real-world evidence category.
News Pfizer's breast cancer drug step closer to EU approval Ibrance is already Pfizer's top oncology product.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
